McKesson EVP Paul C. Julian Sells 21,057 Shares (MCK)
McKesson (NYSE:MCK) EVP Paul C. Julian sold 21,057 shares of the company’s stock on the open market in a transaction dated Thursday, May 29th. The stock was sold at an average price of $186.89, for a total transaction of $3,935,342.73. Following the completion of the transaction, the executive vice president now directly owns 57 shares in the company, valued at approximately $10,653. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
McKesson (NYSE:MCK) traded up 0.57% during mid-day trading on Friday, hitting $189.64. The stock had a trading volume of 1,272,897 shares. McKesson has a 52 week low of $109.82 and a 52 week high of $189.74. The stock’s 50-day moving average is $173.8 and its 200-day moving average is $170.8. The company has a market cap of $43.726 billion and a P/E ratio of 34.80.
McKesson (NYSE:MCK) last posted its quarterly earnings results on Monday, May 12th. The company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.40 by $0.15. The company had revenue of $38.14 billion for the quarter, compared to the consensus estimate of $35.89 billion. During the same quarter in the previous year, the company posted $1.45 earnings per share. The company’s revenue for the quarter was up 25.0% on a year-over-year basis. On average, analysts predict that McKesson will post $10.65 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Tuesday, July 1st. Shareholders of record on Monday, June 9th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.51%. The ex-dividend date is Thursday, June 5th.
A number of research firms have recently commented on MCK. Analysts at Zacks reiterated a “neutral” rating on shares of McKesson in a research note on Thursday, May 15th. They now have a $187.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of McKesson in a research note on Tuesday, May 13th. They now have a $215.00 price target on the stock, up previously from $210.00. Finally, analysts at Morgan Stanley reiterated an “overweight” rating on shares of McKesson in a research note on Tuesday, May 13th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $189.93.
McKesson Corporation delivers pharmaceuticals, medical supplies and healthcare information technologies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.